Nanette Santoro, MD, lifts the results of Fezolinetant, from the pooled analysis of the program attempts to develop Skylight development in phase 3

Fezolinetant is a non-hormone selective neurocinine-3 receptor (NK3R) -Tant, which is approved for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. In the results of a newly pooled analysis of central clinical phase-3 studies that the senior author Nanette F Santoro, MD, during the American College of Obstricians and Gynecologists 2025, annually clinically and scientifically, from May 16 to 18. Visceral fat. In an interview with Patient care^© At the ACOG meeting, Santoro explained that the 2-week study periods, when the 2 measurements of the obesity took, the total weight of the participants and the body mass index remained relatively stable, a positive trend in women who went through menopause.

Both the weight gain and Patient care. These conditions include insulin resistance, type -2 -diabetes, high blood pressure and hyperlipidemia, added.

In the short video above, Santoro underlines the results of the pooled analysis of the Skylight Phase 3 program for the clinical development skylight 1, Skylight 2 and Skylight 4-, which together rated the long-term security and effectiveness of Fezolinetan 45 mg a day. The analysis comprised 1,830 women after menopause who were Fezolinetan for up to 52 weeks.

The following transcript was easily processed for clarity.

Nanette F Santoro, MD, is Professor and E. Stewart Taylor chairman in the departments of reproductive endocrinology and infertility and reproductive sciences, department for obstetrics and gynecology, at the Medical Campus of the University of Colorado Anschutz.

Santoro: The purpose of this study was a secondary analysis. The primary analysis had already evaluated hot flashes, so that this follow-up examined whether Fezolinetan had an impact on body size, body weight and a metric called Body Roundness Index (BRI). Bri is a way to appreciate body shape or scope, similar to the ratio of waist to hip, with which many people are better familiar. BRI essentially contains the same concept.

This analysis included all women who were enclosed in the central Fezolinetant studies both in the 30 mg and in 45 mg doses. The original studies lasted 12 weeks in which women randomized on placebo or one of the two doses of Fezolinetan. After 12 weeks, those in placebo were made available again in order to receive either the 30 mg or 45 mg dose, and the follow -up examination lasted up to 52 weeks.

Throughout the year, the BMI remained relatively stable in all groups – no significant change, regardless of whether the participants were on placebo or Fezolinetan. After 52 weeks, however, we observed a decrease in Body Roundness Index. And it wasn't just a tiny change. This indicates that there may be a change in the shape of the body, although the total weight has not changed. In particular, the reduction seemed to be in the waist size – a change that most women would probably see as positive.

This was a post -hoc analysis, so no statistical tests were carried out. This means that we cannot draw any fixed conclusions, but the results can still make sense and indicate an area that is worth further studying. For example, do we see a loss of visceral fat? If Fezolinetant leads to a reduction in the central fat, this would be an important health marker.

We also know that Fezolinetant improves sleep. It is possible – even if not shown in this study – that better sleep could lead to lower cortisol levels and less belly fat. Poor sleep is associated with a higher risk of metabolic syndrome, including central obesity, increased blood pressure, dyslipidemia and insulin resistance. So it is plausible that some of the observed changes in the body shape could indirectly reflect the metabolic advantages driven by improved sleep.